207922-76-7

Usage

Derivative of N-methylacetamide

The compound is derived from N-methylacetamide, which means it is a modified version of the parent compound, with additional functional groups or substituents added to its structure.

Phenyl ring

The compound contains a phenyl ring, which is a six-membered carbon ring with alternating single and double bonds. This is a common structural motif in many organic compounds and is known for its stability and aromaticity.

Potential pharmaceutical applications

2-[4-(2-amino-ethoxy)-phenyl]-N-methyl-acetamide has potential uses in the development of new drugs, particularly those targeting specific receptors or enzymes. This is due to its unique structure and functional groups, which may allow it to interact with biological targets in novel ways.

Promising candidate for research and development

The compound's structure and functional groups make it a promising candidate for further research and development in the field of medicinal chemistry. This could lead to the discovery of new therapeutic agents for various diseases or disorders.

Therapeutic potential

Additional studies may reveal the compound's potential as a therapeutic agent, providing new treatment options for patients suffering from various diseases or disorders.

Upstream product

• 207922-74-5 methyl 4-(2-(N-benzyloxycarbonylamino)ethoxy)phenylacetamide 

Downstream Products

• 207922-87-0 N-methyl 4-(2-(2-(2-acetylaminopyridin-5-yl)-2-(R)-hydroxyethyl-N-tert-butyloxycarbonylamino)-ethoxy)-phenylacetamide 
• 263898-21-1 2-(4{2-[2-(6-Acetylamino-pyridin-3-yl)-2(R)-(t-butyldimethylsilyloxy)-ethylamino]-ethoxy}-phenyl)-N-methyl-acetamide 

Relevant academic research and scientific papers

Combinations of β3 agonists and growth hormone secretagogues

This invention is directed to pharmaceutical compositions comprising β3adrenergic agonists including (4-(2-(2-(6-aminopyridin-3-yl)-2(R)-hydroxyethylamino)ethoxy)phenyl)acetic acid and growth hormone or growth hormone secretagogues, prodrugs thereof or pharmaceutically acceptable salts of said compounds or said prodrugs. The invention is also directed to methods of using those compositions in the treatment of obesity, diabetes, hypertension and frailty in animals and particularly in humans.

Compound and process for producing β-adrenergic receptor agonist

A process is provided for preparing a compound of the formula: comprising deprotecting a compound of the formula

Process for substituted pyridines

This invention relates to processes for preparing compounds of the formula (I) and to processes for preparing certain intermediates of the formula wherein R1is nitro, amino or protected amino; R2is H, fluoro, chloro CF3, n

2-amino-pyridine intermediates for beta3-Adrenergic receptor agonists

The instant invention relates to intermediates of Formula II, wherein R1, R2 and R3 are as defined in the specification, and to processes for preparing such intermediates. This invention also relates to processes for prepa

BETA-ADRENERGIC AGONISTS TO REDUCE A WASTING CONDITION

The present invention relates to the use of certain β-adrenergic agonists to reduce a wasting condition in a mammal (e.g., human).

Combination therapy including a specific beta-3 agonist and an anorectic agent

This invention relates to pharmaceutical compositions and methods which have utility in treating obesity in animals and particularly in humans. The invention is particularly directed to such compositions which comprise a mixture of a compound which modifi

Beta-Adrenergic agonists to reduce a wasting condition

The present invention relates to the use of certain β-adrenergic agonists, their pharmaceutically acceptable prodrugs, pharmaceutically acceptable salts of either entity, or pharmaceutical compositions containing any of the foregoing, for the manufacture